Absci Stock Offers High-Risk AI Biotech Exposure With 110% Upside Forecast

The biotech world is a prime target for risk-tolerant investors seeking out companies with the potential for dramatic gains. Firms in this space often either make it big—spiking upon news of a promising trial or a drug that will make it to market—or crash and burn. As a penny stock with a market cap of just $600 million, falls squarely in the high-risk, high-reward category. The firm has also seen success providing AI tools and partnership to other players in the biotech and pharma space, including major pl ...